Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Geovax Labs's share price is €93.525.
Geovax Labs's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 was €0.00. Hence, Geovax Labs's PS Ratio for today is .
The historical rank and industry rank for Geovax Labs's PS Ratio or its related term are showing as below:
STU:E8LA'
s PS Ratio Range Over the Past 10 Years
Min: 0.28 Med: 8.42 Max: 81.24
Current: 0.28
During the past 13 years, Geovax Labs's highest PS Ratio was 81.24. The lowest was 0.28. And the median was 8.42.
STU:E8LA's PS Ratio is ranked better than 98.06% of 929
companies
in the Biotechnology industry
Industry Median: 9.49
vs STU:E8LA: 0.28
During the past 12 months, the average Revenue per Share Growth Rate of Geovax Labs was -100.00% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 12.60% per year.
During the past 13 years, Geovax Labs's highest 3-Year average Revenue per Share Growth Rate was 12.60% per year. The lowest was -7.50% per year. And the median was 2.55% per year.
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Geovax Labs PS Ratio Related Terms
Geovax Labs PS Ratio Historical Data
* Premium members only.
The historical data trend for Geovax Labs's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Geovax Labs's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Geovax Labs PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Geovax Labs's PS Ratio distribution charts can be found below:
* The bar in red indicates where Geovax Labs's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Geovax Labs's Share Price of today is €93.525. Geovax Labs's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. The company is focused on the advancement of GEO-MVA, a Modified Vaccinia Ankara (MVA) vaccine candidate for mpox, smallpox, and other poxviruses. Its flagship clinical program in oncology is Gedeptin, a novel oncolytic solid tumor gene-directed therapy, which recently completed a multicenter Phase 1/2 clinical trial for head and neck cancers. The company is also developing GEO-CM04S1, a next-generation multi-antigen COVID-19 vaccine, which is currently being evaluated in two Phase 2 clinical trials.
27GF Score
Get the complete analysis for STU:E8LA
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:E8LA has been successfully added to your 
